利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.021 秒)

    Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
    1.
    发明授权
    Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction 失效
    用于预防，治疗或逆转神经元功能障碍的药物组合物和方法

    公开(公告)号：US08299062B2

    公开(公告)日：2012-10-30

    申请号：US10943502

    申请日：2004-09-17

    申请人： Franklin Volvovitz

    发明人： Franklin Volvovitz

    IPC分类号： A61K31/27 ,  A61K31/435 ,  A61K31/47 ,  A61K31/55 ,  A61K31/4353 ,  A61K31/4748 ,  A61K31/445 ,  A61K31/5513 ,  A61K31/551 ,  A61K31/216

    CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

    摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTING, TREATING, OR REVERSING NEURONAL DYSFUNCTION
    4.
    发明申请
    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTING, TREATING, OR REVERSING NEURONAL DYSFUNCTION 审中-公开
    药物组合物和预防，治疗或逆转神经功能障碍的方法

    公开(公告)号：US20120264741A1

    公开(公告)日：2012-10-18

    申请号：US13530965

    申请日：2012-06-22

    申请人： Franklin Volvovitz

    发明人： Franklin Volvovitz

    IPC分类号： A61K31/55 ,  A61P39/02

    CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

    摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

    Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
    5.
    发明申请
    Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction 失效
    用于预防，治疗或逆转神经元功能障碍的药物组合物和方法

    公开(公告)号：US20090048234A1

    公开(公告)日：2009-02-19

    申请号：US10943502

    申请日：2004-09-17

    申请人： Franklin Volvovitz

    发明人： Franklin Volvovitz

    IPC分类号： A61K31/55 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4748 ,  A61K31/5513 ,  A61K31/216 ,  A61K31/551 ,  A61K31/445 ,  A61K31/4353 ,  A61K31/47

    CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

    摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

    Method for producing influenza hemagglutinin multivalent vaccines
    7.
    发明授权
    Method for producing influenza hemagglutinin multivalent vaccines 有权
    生产流感血凝素多价疫苗的方法

    公开(公告)号：US06245532B1

    公开(公告)日：2001-06-12

    申请号：US09169027

    申请日：1998-10-09

    申请人： Gale E. Smith ,  Franklin Volvovitz ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett

    发明人： Gale E. Smith ,  Franklin Volvovitz ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett

    IPC分类号： C12N1562

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/035 ,  C07K2319/036 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2710/14143 ,  C12N2760/16122 ,  C12N2760/16222 ,  Y10S977/917

    摘要： A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed for the purification of rHA proteins from A sub-types and B type influenza viruses. The procedure produces substantially pure rHA which is a biologically active hemagglutinin, non-denatured, and suitable as a component in human or other animal influenza vaccines.

    摘要翻译： 提供了使用DNA技术制备重组流感疫苗的方法。 所得疫苗是基于从具有流行潜力的流感病毒克隆的重组血凝素抗原的混合物的多价，优选三价流感疫苗。 重组血凝素抗原是全长，未切割（HA0），由培养的昆虫细胞中的杆状病毒表达载体产生的糖蛋白，并在非变性条件下纯化。 重组疫苗可以从流感的主要来源开发，例如来自感染个体的鼻分泌物，而不是从鸡卵中适应和培养的病毒。 从流感A和B病毒克隆流感血凝素基因的过程使用特别设计的寡核苷酸探针和PCR。 在优选的实施方案中，然后通过缺失天然疏水信号肽序列修饰克隆的HA基因并用新的杆状病毒信号肽代替它们。 还公开了在昆虫细胞中产生的重组HA蛋白的有效提取和纯化的一般方法用于从A亚型和B型流感病毒纯化rHA蛋白。 该程序产生基本上纯的rHA，其是生物活性血凝素，非变性的，并且适合作为人或其他动物流感疫苗中的组分。

    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTING, TREATING, OR REVERSING NEURONAL DYSFUNCTION
    9.
    发明申请
    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTING, TREATING, OR REVERSING NEURONAL DYSFUNCTION 审中-公开
    药物组合物和预防，治疗或逆转神经功能障碍的方法

    公开(公告)号：US20130289021A1

    公开(公告)日：2013-10-31

    申请号：US13853683

    申请日：2013-03-29

    申请人： Franklin Volvovitz

    发明人： Franklin Volvovitz

    IPC分类号： A61K31/439 ,  A61K31/5513 ,  A61K31/46 ,  A61K31/216 ,  A61K45/06 ,  A61K31/4453

    CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

    摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

    Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
    10.
    发明申请
    Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction 审中-公开
    用于预防，治疗或逆转神经元功能障碍的药物组合物和方法

    公开(公告)号：US20080090808A1

    公开(公告)日：2008-04-17

    申请号：US11584017

    申请日：2006-10-17

    申请人： Franklin Volvovitz

    发明人： Franklin Volvovitz

    IPC分类号： A61K31/55 ,  A61K31/4745 ,  A61K31/4709

    CPC分类号： A61K31/4745 ,  A61K31/4709 ,  A61K31/55 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

    摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。